Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13252835 | 1.00 | MAPT (0.58) | MAPTRAB9APSMD10TDP1L3MBTL1 | |
| SCHEMBL30325226 | 1.00 | MAPT (0.58) | MAPTRAB9APSMD10TDP1L3MBTL1 | |
| SCHEMBL29084498 | 0.96 | MAPT (0.63) | MAPTRAB9APSMD10TDP1L3MBTL1 | |
| SCHEMBL29768658 | 0.90 | PSMD10 (0.59) | MAPTRAB9APSMD10TDP1L3MBTL1 | |
| SCHEMBL13252830 | 0.89 | CA12 (0.47) | MAPTRAB9APSMD10TDP1L3MBTL1 | |
| SCHEMBL13873578 | 0.89 | GAA (0.54) | MAPTTDP1L3MBTL1CA12CA1 | |
| SCHEMBL29768597 | 0.89 | PSMD10 (0.58) | MAPTRAB9APSMD10TDP1L3MBTL1 | |
| SCHEMBL30244540 | 0.87 | CA12 (0.46) | MAPTRAB9APSMD10TDP1L3MBTL1 | |
| SCHEMBL30244725 | 0.87 | CA12 (0.46) | MAPTRAB9APSMD10TDP1L3MBTL1 | |
| SCHEMBL29768570 | 0.86 | TCF4 (0.50) | MAPTRAB9APSMD10ALDH1A1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136619-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2023059581-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136619-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | CDK9, AURKB, AURKC | MAPT 912/4885RAB9A 156/4885PSMD10 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.